• HIV 1 infection in combination with other antivirals:
    • Adults & >16 years: PO 200mg OD *2/52, then if no rash increase to 200mg BD
      • If rash occurs wait until it is resolved before increasing
    • ≥15 days- 6 years: PO 150mg/m² OD *2/52, then if no rash, then increase to 150mg/m² BD
      • Max 200mg/dose
  • Prevention of maternal-fetal HIV transmission in women with no prior antiretroviral treatment:
    • PO 200mg as a single dose at onset of labor
      • Used with IV zidovudine
  • Prevention of maternal-fetal HIV transmission in neonates (3 drug regimen):
    • 34-37 wk gestation: PO 8mg/kg/day divided BD*1/52, then 12mg/kg/day BD *1-5 weeks
    • >37 week gestation: PO 12mg/kg/day divided BD *2-6 weeks
    • Initiated within 12 hours after birth
    • Given with lamivudine and zidovudine
  • Prevention of maternal-fetal HIV transmission in neonates (2 drug regimen):
    • Birth weight 1.5-2 kg: PO 8mg/dose
    • Birth weight >2 kg: PO 12mg/dose
    • Administer 3 doses in the first week of life, 1st dose 48 hours after birth, give 2nd dose 48 hours after 1st dose and 3rd dose 96 hours after 2nd dose
      • Recommended in combination with 6 weeks of zidovudine
  • Tablet:
    • 200mg
  • Suspension:
    • 50mg/5mL
  • Shake suspension gently and administer entire measured dose
  • To be taken with/without food

Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

It inhibits reverse transcriptase and incorporates into viral DNA resulting in DNA chain termination

  • Rash
  • Nausea
  • Elevated ALT/AST
  • Fatigue
  • Headache
  • Anemia
  • Diarrhea
  • Abdominal pain
  • Hepatotoxicity
  • Arthralgia
  • Myalgia
  • Lipodystrophy
  • Pregnancy (treatment-naive patients)
  • Post-exposure prophylaxis use
  • Hepatic impairment, Child-Pugh Class B-C
  • Baseline CD4 >250 (female patients)
  • Baseline CD4 >400 (male patients)
  • Breastfeeding

WARNING

  • Severe, life-threatening and sometimes fatal hepatotoxicity
  • Severe, life-threatening and sometimes fatal skin reactions including Steven-Johnson syndrome, toxic epidermal necrolysis, hypersensitivity reactions with rash, constitutional findings and organ dysfunction
  • Extra vigilance warranted during first 6 week of therapy (period of greatest risk)
  • Artemether/lumefantrine
  • Atazanavir
  • Carbamazepine
  • Cariprazine
  • Cobimetinib
  • Dienogest/estradiol valerate
  • Doravirine
  • Efavirenz
  • Elbasvir/grazoprevir
  • Elvitegravir/cobicistat/emtricitabine/tenofovir df
  • Etravirine
  • Lumacaftor/ivacaftor
  • Lumefantrine
  • Lurasidone
  • Naloxegol
  • Ombitasvir/paritaprevir/ritonavir & dasabuvir
  • Panobinostat
  • Praziquantel
  • Regorafenib
  • Rilpivirine
  • Roflumilast
  • Vandetanib

                          Drug Status

Availability Prescription only
Pregnancy Contraindicated in treatment-naive patients; Category B
Breastfeeding Contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Nevimune 200mg Tablet 60’s Cipla Limited Cipla Limited
Nevimune 50mg/5mL Suspension 100mL Cipla Limited Cipla Limited
Nevirapine 200mg Tablet 60’s Aurobindo Pharma Simba Pharma
Nevirapine 50mg/5mL Suspension 240mL Aurobindo Pharma Simba Pharma
Neviriv 200mg Tablet 60’s Cosmos Ltd Cosmos Ltd